Cancer News and Research

Latest Cancer News and Research

Study: Chemotherapy can improve survival rate in older adolescents with leukemia

Research led by St. Jude Children-s Research Hospital investigators will likely impact how acute lymphoblastic leukemia is treated in young adults and shows older adolescent age does not dictate worse outcomes against the most common childhood cancer.

21 Dec 2010

New predictive medicine product for hereditary pancreatic and related cancers

Myriad Genetics, Inc. today announced the launch of PANEXIA™, a predictive medicine product for hereditary pancreatic and related cancers. PANEXIA is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. PANEXIA, Myriad's ninth molecular diagnostic product, is the second product launched by the Company this year.

21 Dec 2010

Researchers develop new lung imaging technique that causes minimum tissue disruption

Fast-moving objects create blurry images in photography, and the same challenge exists when scientists observe cellular interactions within tissues constantly in motion, such as the breathing lung. In a recent UCSF-led study in mice, researchers developed a method to stabilize living lung tissue for imaging without disrupting the normal function of the organ.

21 Dec 2010

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.

21 Dec 2010

EpiCept receives Israeli Ministry of Health approval for Ceplene

EpiCept Corporation today announced that the Israeli Ministry of Health has approved the marketing application for Ceplene®, indicated for remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Megapharm Ltd. is EpiCept's partner in Israel and upon Ministry of Health approval of labeling and other technical matters the company is expected to launch Ceplene® in the first quarter of 2011.

21 Dec 2010

New study finds racial, ethnic disparities in cancer treatment

Black people with early stage liver cancer were more likely than white patients to die from their disease, according to a new study from the University of Michigan Comprehensive Cancer Center.

21 Dec 2010

Robotic surgery as effective as other minimally invasive techniques for head and neck squamous cell carcinomas

Less-invasive robotic surgery for upper airway and digestive track malignant tumors is as effective as other minimally invasive surgical techniques based on patient function and survival, according to University of Alabama at Birmingham researchers.

21 Dec 2010

Hutchinson Center's tips for weight loss in the new year

Losing weight is at the top of many a New Year's resolution list. In addition to maintaining a healthy diet and getting enough exercise, what else can one do to make sure those good intentions have a lasting impact throughout the year?

21 Dec 2010

Ambit commences Phase I advanced solid tumor trials for AC430 and AC480 inhibitors

Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.

20 Dec 2010

DNA tunneling detector embedded in a ‘Nanopore’

Scientists from Imperial College London are developing technology that could ultimately sequence a person's genome in mere minutes, at a fraction of the cost of current commercial techniques.

20 Dec 2010

HistoRx grants Metamark worldwide license to AQUA technology for commercialization of Prognostic Assays

Metamark Genetics, Inc., a privately held oncology-focused molecular diagnostics company, and HistoRx, Inc., a diagnostics company developing tissue-based diagnostic solutions to advance individualized patient care, today announced a multi-year licensing agreement. HistoRx has granted Metamark a worldwide license to the AQUA technology for the clinical commercialization of Metamark's proprietary MetamarkDx™ Prognostic Assays.

20 Dec 2010

Bristol-Myers Squibb, Oncolys complete license agreement for festinavir

Bristol-Myers Squibb Company and Oncolys BioPharma Inc., a privately held biotechnology company based in Japan, announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire exclusive worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV.

20 Dec 2010

Rexahn granted Japanese patent for preclinical compound RX-0047

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it was awarded patent 4,546,454 entitled, "Antisense Oligonucleotides that Inhibit Expression of HIF-1," by the Japanese Patent Office.

20 Dec 2010

Oncothyreon commences combination PX-866/cetuximab Phase 1/2 trial in cancers

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux®). PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

20 Dec 2010

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.

20 Dec 2010

Gilead to acquire Arresto

Gilead Sciences, Inc. and Arresto Biosciences, Inc., a privately-held, development-stage biotechnology company focused on medicines to treat fibrotic diseases and cancer, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Arresto. Under the terms of the agreement, Gilead will acquire Arresto for $225 million and potential future payments based on achievement of certain sales levels.

20 Dec 2010

Spectrum Pharmaceuticals to be traded on NASDAQ Global Select Market

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that effective January 3, 2011, it will begin trading on the NASDAQ Global Select Market. The NASDAQ Global Select Market is the highest NASDAQ listing tier based on financial and liquidity criteria. Prior to the effectiveness of this change in the New Year, shares of Spectrum Pharmaceuticals will continue to be traded on the NASDAQ Global Market.

20 Dec 2010

Aeterna Zentaris reaches agreement with FDA for Solorel SPA as a diagnostic test in AGHD

Aeterna Zentaris Inc. today announced that it has reached agreement with the Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for Solorel® (AEZS-130, macimorelin) which will enable the Company to complete the ongoing registration study required to gain approval as a diagnostic test for Adult Growth Hormone Deficiency (AGHD).

20 Dec 2010

Arrowhead launches new company, Ablaris to commercialize novel weight loss technology

Arrowhead Research Corporation today announced that it has executed an exclusive world-wide license on technology developed by Drs. Wadih Arap and Renata Pasqualini at MD Anderson Cancer Center for use in weight loss and obesity-related metabolic conditions, and that it has launched a new company, Ablaris Therapeutics Inc., to commercialize this platform.

20 Dec 2010

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.

20 Dec 2010

Cancer News and Research

Latest Cancer News and Research

Study: Chemotherapy can improve survival rate in older adolescents with leukemia

New predictive medicine product for hereditary pancreatic and related cancers

Researchers develop new lung imaging technique that causes minimum tissue disruption

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

EpiCept receives Israeli Ministry of Health approval for Ceplene

New study finds racial, ethnic disparities in cancer treatment

Robotic surgery as effective as other minimally invasive techniques for head and neck squamous cell carcinomas

Hutchinson Center's tips for weight loss in the new year

Ambit commences Phase I advanced solid tumor trials for AC430 and AC480 inhibitors

DNA tunneling detector embedded in a ‘Nanopore’

HistoRx grants Metamark worldwide license to AQUA technology for commercialization of Prognostic Assays

Bristol-Myers Squibb, Oncolys complete license agreement for festinavir

Rexahn granted Japanese patent for preclinical compound RX-0047

Oncothyreon commences combination PX-866/cetuximab Phase 1/2 trial in cancers

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Gilead to acquire Arresto

Spectrum Pharmaceuticals to be traded on NASDAQ Global Select Market

Aeterna Zentaris reaches agreement with FDA for Solorel SPA as a diagnostic test in AGHD

Arrowhead launches new company, Ablaris to commercialize novel weight loss technology

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Industry Focus: Cell & Gene Therapy eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cancer News and Research

Latest Cancer News and Research

Industry Focus: Cell & Gene Therapy eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in